Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women age 18 and over~* Diagnosed with Interstitial Cystitis as defined by protocol~* Able and willing to complete questionnaires and diary~* Able to comply with visit schedule including Day 14 Removal visit~* Completion of blinded study prior to enrolling in unblinded part of study~Exclusion Criteria:~* Pregnant or lactating women~* Bladder or urethra anatomical feature that would prevent the safe indwelling or insertion of the investigational product~* History or presence of any condition that would make it difficult to evaluate symptoms~* Did not complete blinded study (unblinded part of study only)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine Releasing Intravesical System (Type: EXPERIMENTAL): Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
- LiRIS containing inactive substance only (Type: PLACEBO_COMPARATOR): LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
- Cystoscopy Procedure (Type: SHAM_COMPARATOR): No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.

Based on this trial design, predict the completion outcome and termination type (if applicable).